Research graph
References from Targeting RAB27A Enhances Pembrolizumab Sensitivity and Alleviates Immune Escape via Inactivation of the PI3K /Akt/ mTOR Pathway in Triple‐Negative Breast Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2024 · External reference
Global Burden and Trends of Breast Cancer: GLOBOCAN 2022 Estimates of Incidence and Mortality in 185 Countries
10.1097/cm9.0000000000003921 · 2026 · External reference
Triple‐Negative Breast Cancer: Current Understanding and Future Perspectives
10.37349/etat.2026.1002372 · 2026 · External reference
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients With Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025
2026 · External reference
Immunotherapy Innovations in Triple‐Negative Breast Cancer: Targeting Checkpoints, Combinations, and Biomarkers
10.3389/or.2026.1802090 · 2026 · External reference
PD‐1/PD‐L1 Inhibitor‐Based Immunotherapy in Locally Advanced or Metastatic Triple‐Negative Breast Cancer: A Meta‐Analysis
10.3892/ol.2024.14803 · 2025 · External reference
Immune Checkpoint Inhibitors and Chemotherapy Versus Chemotherapy for Early Triple‐Negative Breast Cancer
2026 · External reference
Immunotherapy in Triple‐Negative Breast Cancer: Mechanisms of Resistance and Emerging Approaches: A Narrative Review
10.12701/jyms.2026.43.17 · 2026 · External reference
Immunotherapy in Triple‐Negative Breast Cancer: From Molecular Mechanisms to Precision Medicine‐Overcoming Resistance and Optimizing Clinical Outcomes
10.1016/j.critrevonc.2026.105174 · 2026 · External reference
Deglycosylated PD‐L1 Is a Biomarker for Immune Checkpoint Blockade Response: A Real‐World Study in Breast Cancer Patients in Taiwan
10.1016/j.canlet.2025.217912 · 2025 · External reference
The Incidence and Risk of Cardiovascular Events Associated With Pembrolizumab in Patients With Breast Cancer
10.1016/j.canlet.2024.217277 · 2025 · External reference
Immunotherapy Resistance in Triple‐Negative Breast Cancer: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Implications
10.3389/fonc.2025.1630464 · 2025 · External reference
The PI3K/Akt/mTOR Signaling Pathway in Triple‐Negative Breast Cancer: A Resistance Pathway and a Prime Target for Targeted Therapies
10.3390/cancers17132232 · 2025 · External reference
PI3K/AKT/mTOR Signaling Pathway: An Important Driver and Therapeutic Target in Triple‐Negative Breast Cancer
10.1007/s12282-024-01567-5 · 2024 · External reference
The Immune Checkpoint TIGIT/CD155 Promotes the Exhaustion of CD8 + T Cells in TNBC Through Glucose Metabolic Reprogramming Mediated by PI3K/AKT/mTOR Signaling
10.1186/s12964-023-01455-z · 2024 · External reference
Eganelisib Combined With Immune Checkpoint Inhibitor Therapy and Chemotherapy in Frontline Metastatic Triple‐Negative Breast Cancer Triggers Macrophage Reprogramming, Immune Activation and Extracellular Matrix Reorganization in the Tumor Microenvironment
10.1136/jitc-2024-009160 · 2024 · External reference
Combination Therapy With PD‐1 Inhibition Plus Rapamycin and Metformin Enhances Anti‐Tumor Efficacy in Triple Negative Breast Cancer
10.1016/j.yexcr.2023.113647 · 2023 · External reference
Functional Implications of Rab27 GTPases in Cancer
10.1186/s12964-018-0255-9 · 2018 · External reference
Rasal2 Inhibits Autophagic‐Exosomes Secretion via Regulating Rab27a in Triple‐Negative Breast Cancer Progression
10.1186/s12967-025-06530-2 · 2025 · External reference
Targeting TYK2 Alleviates Rab27A‐Induced Malignant Progression of Non‐Small Cell Lung Cancer via Disrupting IFNα‐TYK2‐STAT‐HSPA5 Axis
10.1038/s41698-024-00574-1 · 2024 · External reference
miR‐4454 Promotes Hepatic Carcinoma Progression by Targeting Vps4A and Rab27A
10.1155/2021/9230435 · 2021 · External reference
RAB27A Promotes the Proliferation and Invasion of Colorectal Cancer Cells
10.1038/s41598-022-23696-7 · 2022 · External reference
Silencing RAB27a Inhibits Proliferation, Invasion and Adhesion of Triple‐Negative Breast Cancer Cells
2023 · External reference
Tumor Extracellular Vesicles Mediate Anti‐PD‐L1 Therapy Resistance by Decoying Anti‐PD‐L1
10.1038/s41423-022-00926-6 · 2022 · External reference
Upregulation of Exosome Secretion From Tumor‐Associated Macrophages Plays a Key Role in the Suppression of Anti‐Tumor Immunity
10.1016/j.celrep.2023.113224 · 2023 · External reference
MiR‐124‐3p Impedes the Metastasis of Non‐Small Cell Lung Cancer via Extracellular Exosome Transport and Intracellular PI3K/AKT Signaling
10.1186/s40364-022-00441-w · 2023 · External reference
Campothecin Suppresses Cell Proliferation and Migration in Head and Neck Squamous Cell Carcinoma by Blocking RAB27A‐Mediated Phosphatidylinositol 3 Kinase (PI3K)/Protein Kinase B (AKT) Pathway
2024 · External reference
Galangin Modulates the NRF2/PPAR‐Γ Pathway, Attenuating Sepsis‐Induced Tissue Damage in the Lungs
10.1007/s11033-026-11931-7 · 2026 · External reference
RAB27A and RAB27B Expression May Predict Lymph Node Metastasis and Survival in Patients With Gastric Cancer
10.21873/cgp.20345 · 2022 · External reference
RAB27B Expression in Pancreatic Cancer Is Predictive of Poor Survival but Good Response to Chemotherapy
10.3233/cbm-220460 · 2023 · External reference
Spatial Profiling Reveals Unique Immune Microenvironment in Premenopausal Triple‐Negative Breast Cancer Associated With Therapy Response
10.1186/s12967-025-06786-8 · 2025 · External reference
SH3BGRL3 Promotes Radioresistance and Immune Evasion in Triple‐Negative Breast Cancer by Regulating Rab27a
10.1186/s13062-026-00799-z · 2026 · External reference
RAB27A Promotes Melanoma Cell Invasion and Metastasis via Regulation of Pro‐Invasive Exosomes
10.1002/ijc.32064 · 2019 · External reference
Exosome‐Mediated Secretion of miR‐127‐3p Regulated by RAB27A Accelerates Metastasis in Renal Cell Carcinoma
10.1186/s12935-024-03334-0 · 2024 · External reference
Signaling Networks Regulating Metastatic Progression in Triple‐Negative Breast Cancer
10.3390/cells15090809 · 2026 · External reference
Munc13‐4 Mediates Tumor Immune Evasion by Regulating the Sorting and Secretion of PD‐L1 via Exosomes
10.1038/s41467-025-64149-9 · 2025 · External reference
Clinical Implications of the Interaction Between PD‐1/PD‐L1 and PI3K/AKT/mTOR Pathway in Progression and Treatment of Non‐Small Cell Lung Cancer
10.7150/jca.77619 · 2022 · External reference
G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC‐I via PI3K/Akt Activation in Bladder Cancer
2024 · External reference
Loss of MHC‐I Antigen Presentation Correlated With Immune Checkpoint Blockade Tolerance in MAPK Inhibitor‐Resistant Melanoma
10.3389/fphar.2022.928226 · 2022 · External reference
Infiltration Characteristics and Regulatory Mechanisms of CD8(+) T Lymphocytes in Solid Tumors: Spatial Distribution, Biological Functions, and Interactions With the Immune Microenvironment
10.3389/fimmu.2025.1661545 · 2025 · External reference
CD8(+) T‐Cell Exhaustion: Impediment to Triple‐Negative Breast Cancer (TNBC) Immunotherapy
10.1016/j.bbcan.2024.189193 · 2024 · External reference
Retrospective Comparison Between Breast Cancer Tissue‐ and Blood‐Based Next‐Generation Sequencing Results in Detection of PIK3CA, AKT1, and PTEN Alterations
10.1186/s13058-025-02055-0 · 2025 · External reference
Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple‐Negative Breast Cancer
10.3390/ijms23137353 · 2022 · External reference
Treatment Strategies Targeting the Phosphoinositide 3‐Kinase/Protein Kinase B/Mechanistic Target of Rapamycin Pathway Against Triple‐Negative Breast Cancer
2025 · External reference
